Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2016

View Archived Issues

Fostamatinib meets primary endpoint in the first study from the FIT phase III clinical program

NIAID awards grant to Hawaii Biotech for chikungunya virus vaccine research

FDA approves Afluria Quadrivalent influenza vaccine for people 18 years of age and older

FDA approves biosimilar etanercept Erelzi

Oblato's disufenton sodium receives FDA orphan drug designation

OPKO Health completes Transition Therapeutics acquisition

Merck Patent discloses NUDT1 inhibitors

Nanjing Gator Meditech and Jilin University patent PI3Kdelta inhibitors

Ningbo Wenda Pharmaceutical Technology develops EGFR inhibitors

FDA accepts NDA for edaravone in ALS

Yissum Research Development reports anticancer agents

Ariad completes rolling NDA submission for brigatinib

Sunshine Lake Pharma describes FXR agonists

Nymox's fexapotide shows clinically meaningful benefits in BPH

rAAV6-INT41 intrabody therapy shows promise in vivo for Huntington's disease

Debiopharm invests in start-up diagnostics company GenePOC

Merck KGaA discovers potent and selective inhibitors of the kinase GCN2

FDA accepts BLA for CSL-830

GlaxoSmithKline tests novel antimalarial quinazolindiones

ONO Pharmaceutical develops GABA(A) alpha-5 negative allosteric modulators

FDA responts to Oragenic's request for type C meeting

Valeant will commercialize Contrave in Canada under an agreement with Orexigen

DNA methylation-based assay significantly improves diagnosis of cancer of unknown primary

Kamada reports positive results on inhaled alpha-1 antitrypsin phase II trial

Arbutus Biopharma terminates exclusive license agreement with Kuros Biosciences

Novel desmin mutation causes left-dominant arrhythmogenic cardiomyopathy

FDA grants orphan drug designation to Genentech's etrolizumab

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026